PubRank

David H Lawson

Author PubWeight™ 26.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011 5.15
2 Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002 3.24
3 Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol Psychiatry 2003 2.05
4 Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 2003 1.90
5 Basal ganglia hypermetabolism and symptoms of fatigue during interferon-alpha therapy. Neuropsychopharmacology 2007 1.63
6 Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody). J Immunother 2009 1.36
7 Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases. Am J Clin Oncol 2017 0.94
8 Utility of lymph node assessment for atypical spitzoid melanocytic neoplasms. Ann Surg Oncol 2010 0.92
9 Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med 2012 0.87
10 Rising incidence of mucosal melanoma of the head and neck in the United States. J Skin Cancer 2012 0.87
11 Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma. Am J Clin Oncol 2014 0.86
12 Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma. J Immunother 2015 0.86
13 Melanoma growth stimulatory activity in primary malignant melanoma: prognostic significance. Mod Pathol 2002 0.85
14 The emerging role of radiotherapy for desmoplastic melanoma and implications for future research. Melanoma Res 2015 0.84
15 BRAF inhibitor and stereotactic radiosurgery is associated with an increased risk of radiation necrosis. Melanoma Res 2016 0.82
16 The impact of escitalopram on IL-2-induced neuroendocrine, immune, and behavioral changes in patients with malignant melanoma: preliminary findings. Neuropsychopharmacology 2013 0.78
17 Prognostic value of 18f-fluorodeoxyglucose positron emission tomography-computed tomography in predicting survival in patients with unresectable metastatic melanoma to the liver undergoing yttrium-90 radioembolization. J Vasc Interv Radiol 2012 0.78
18 Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study. Am J Clin Oncol 2017 0.77
19 Complete response to high-dose IL-2 and enhanced IFNγ+Th17 :  TREG ratio in a melanoma patient. Melanoma Res 2016 0.76
20 The influence of postoperative lymph node radiation therapy on overall survival of patients with stage III melanoma, a National Cancer Database analysis. Melanoma Res 2016 0.76
21 Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. Melanoma Res 2016 0.75
22 Exogenous IL-2 Induces FoxP3+ Th17 Cells In Vivo in Melanoma Patients. J Immunother 2016 0.75
23 Interferon Alfa-2b or not 2b? Significant differences exist in the decision-making process between melanoma patients who accept or decline high-dose adjuvant interferon Alfa-2b treatment. Dermatol Surg 2007 0.75
24 Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E. Melanoma Res 2017 0.75
25 Plasma homocysteine and immune activation in patients with malignant melanoma undergoing treatment with IFN-alpha. J Interferon Cytokine Res 2004 0.75